ClinicalTrials.Veeva

Menu

Inflammasomes in Cell Death in FTMH, ERM, and RRD

A

Allen C. Ho, MD

Status

Completed

Conditions

Retinal Detachment
Epiretinal Membrane
Full Thickness Macular Hole

Treatments

Procedure: Pars plana vitrectomy
Procedure: External drainage

Study type

Observational

Funder types

Other

Identifiers

NCT03332758
17-660E

Details and patient eligibility

About

Prospective study evaluating the role of inflammasomes in cell death in retinal detachment, full thickness macular hole, and epiretinal membrane. The investigators are collecting vitreous and subretinal fluid samples from patients with these conditions and evaluating activity of the inflammasome pathway with established assays.

Full description

Photoreceptor cell death is the main cause of vision loss in many retinal disorders, including retinal detachment (RD). While apoptosis is the most studied form of cell death, the investigators believe patients with RDs may have photoreceptor cell death from a distinct pathway of programmed cell death called pyroptosis which also involves an inflammatory response. Pyroptosis is distinct from apoptosis in that it requires the activation of a protein oligomer complex called an inflammasome. The inflammasome is a pro-inflammatory complex composed of apoptosis-associated speck-like protein containing a CARD (ASC), nucleotide-binding oligomerization domain-containing protein (NOD)-like receptor (NLR) family or pyrin and HIN domain (PYHIN) family, and caspase-11. Activation of the inflammasome complex leads to activation of capspase 1 proteolytic activity to cleave and synthesize IL-1β and IL-18. As such the investigators believe inflammasomes and its activated products may play a strong role in the inflammatory and cell death pathway for photoreceptor cells in human retina. Studies using animal models of RD have already confirmed the presence of IL-1β activation2, however, the presence of IL-18 needs to be confirmed in human detached retinas. In a study performed on the detached retinas in mice, researchers were able to show activation of inflammasomes leading to photoreceptor cell death. While researchers are unable to determine the cellular source of the inflammasomes they were able to show that activation inflammasomes closely follows animal models. Currently there is no method to rescue photoreceptors cells from the mediated cell death pathway despite surgical intervention. Thus, current visual prognosis and prevention of further photoreceptor loss due to a RD is likely dependent on the time of surgical intervention before further detachment and further cell death can occur. As such, the purpose of this current study is to confirm the presence of inflammasome activation as well as the synthesis of its products, IL-1β and IL-18, in patients with rhegmatogenous retinal detachments. Both inflammasomes and its products IL-1β and IL-18 may be involved in cell pyroptosis, a programmed cell death distinct from apoptosis. Due to a lack of treatment for the rescue of photoreceptor cells from cell death after a retinal detachment, this study can provide novel strategies to inhibit cell death.

Enrollment

41 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patient of the Wills Eye Hospital Retina service and Mid-Atlantic Retina offices.
  2. Volunteer patients age 18 years and older.
  3. Healthy enough to participate in the study.
  4. Willing and able to consent to participation in the study.
  5. Diagnosis of rhegmatogenous retinal detachment treated with external drainage of subretainl fluid, rhegmatogenous retinal detachment treated with pars plana vitrectomy, or full thickness macular hole treated with pars plana vitrectomy

Exclusion criteria

  1. Presence of tractional retinal detachment
  2. History of trauma
  3. Presence of proliferative vitreoretinopathy
  4. History of prior retinal detachment repair or any prior retina surgery or laser treatment e. Any preexisting retinal disease (including diabetic retinopathy, age related macular degeneration, retinal vein or artery occlusion, other retinal vascular disease, inherited retinal degeneration, uveitis)

Trial design

41 participants in 4 patient groups

RD treated with vitrectomy
Description:
Vitreous fluid from retinal detachment treated with pars plana vitrectomy
Treatment:
Procedure: Pars plana vitrectomy
RD treated with external drainage
Description:
Subretinal fluid from retinal detachment treated with external drainage.
Treatment:
Procedure: External drainage
Macular holes treated with vitrectomy
Description:
Vitreous fluid from patients treated for macular hole
Treatment:
Procedure: Pars plana vitrectomy
ERM treated with vitrectomy
Description:
Vitreous fluid from patients treated for epiretinal membrane
Treatment:
Procedure: Pars plana vitrectomy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems